Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | ARV-771 + Enzastaurin |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| ARV-771 | ARV 771|ARV771 | BET Inhibitor (Pan) 33 | ARV-771 is a bifunctional molecule that targets BET proteins for proteolytic degradation, resulting in reduced target gene expression and potentially leading to increased apoptosis and reduced tumor growth (PMID: 31217338, PMID: 27274052, PMID: 30575820). | |
| Enzastaurin | LY317615|LY-317615 | PKC beta Inhibitor 6 | Enzastaurin (LY317615) is a selective inhibitor PKC-beta, with activity against other PKC isoforms at higher concentrations, which decreases downstream signaling and potentially results in reduced tumor growth (PMID: 16103100, PMID: 17671157, PMID: 22253748, PMID: 32250167). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|